Complete Prepacked Two Chamber PET-Carbonylation Kits Based on a Trap/Release of (11C)-Carbon Monoxide on a Solid Support

Description:

Complete Prepacked Two Chamber PET-Carbonylation Kits Based on a Trap/Release of (11C)-Carbon Monoxide on a Solid Support

 

Technical Field

 

PET, Biotech, Pharma

 

Business opportunity

 

Research collaboration to validate the technology

 

Current state of technology

 

Currently, the project has developed a prototype of the invention. In addition, a range of biologically important carbon-11 carbonyl labelled compounds has been synthesized utilizing the methodology.

 

Commercial Value

 

Nuclear medicine and PET represent two of the most widely used molecular imaging modalities in clinical practice. Molecular imaging is a unique form of diagnostic imaging that enables the characterization and measurement of biological processes at the cellular and molecular levels.While nuclear medicine has been recognized as a branch of medicine since the early 1970s, PET is a relatively young market which did not begin gaining widespread acceptance as a clinically viable tool in medicine until the mid-1990s.

 

In 2010, a total of 726 nuclear and PET imaging systems was shipped within the US, with a revenue of 552.4 Mio dollar. US market revenues have declined at a CAGR of 4.7 percent from 2007 to 2010 due to the continuing recession. Projections are at a CAGR of 4.9 percent from 2010 to 2017. Growth expectations for PET are primarily based an expected increase in demand due to increased clinical scope and improved cost efficiency.

 

The Technology

 

A positron emission tomography (PET) scan is an imaging test that can help reveal physiological information regarding how patients tissues and organs are functioning. However, the technique is limited as there are not many molecules that can be labelled with radioisotopes. Approximately 85% of all PET examinations are performed with a single 18F-labelled sugar analogue.

 

Not only are there not many tracer molecules, but there are problems with the current ones, as many are made by methylation or fluorination of a natural product. This changes the structure of the compound, therefore possibly changing the mechanism of action. This can cause a range of problems, for example, in relation to regulatory requirements. An alternative to 18-F and 11-C methylation is 11-C carbonyl labelling, as this can be done without modifying the chemical structure ? however, the methods of 11-C carbonyl labelling are complex, limited and require sophisticated equipment.

 

Intellectual Property Rights

 

Aarhus University has filed a patent application in the US, with priority date Sep 2011 and this has proceeded through the PCT phase.

 

Patent Information:
For Information, Contact:
Eoin Galligan
Business Development Manager
Aarhus University
+45 60202690
ega@au.dk
Inventors:
Troels Skrydstrup
Anders Thyboe Lindhardt
Thomas Gøgsig
Rolf Taaning
Hélène Audrain
Dirk Andreas Bender
Keywords:
z_DoNotUse_Chemistry
z_DoNotUse_Pharma
© 2026. All Rights Reserved. Powered by Inteum